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Abstract
EGFR is a key player in the signalling cascades of various kinds of cancers and tyrosine kinase inhibitors block EGFR
signalling. Natural products have long been used as candidates for therapy in the management of cancer. Violacein, a
bacterial pigment, has been known for its numerous biological applications such as antimicrobial, antileishmanial,
antiviral, as well as antitumoral. Computational studies have concluded that it may have activity against cancers like
pancreatic cancer, thyroid cancer, colorectal cancer, and endometrial cancer indicating its potential application as a broad
range of anti-cancerous drug. This study aimed to perform the molecular docking of violacein with the EGFR protein to
ascertain its EGFR inhibitor property, which could lead to the development of a novel anti-cancer drug.
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1. Introduction
Cancer has been a global public health concern and
currently ranks second among the leading causes of
death. The WHO estimates around 27 million cancer
incidences by 2050, with an annual mortality rate of
17.5 million individuals [1]. Even though there are
numerous treatment options for cancer, there are
not any without side effects. Natural products have
long been used as candidates for therapy in the
management of cancer and other diseases such as
diabetes, cardiovascular disease, and multiple sclerosis to name a few. Natural compounds are reported to possess unique advantages and
characteristics over synthetic substances [2]. Natural
pigments have proven multifaceted applications in
medicines, foods, clothes, furniture, cosmetics, and
other product [3].
Violacein, a bacterial pigment, is a bisindole
purple-colored natural compound that is being
studied for its several biological functions. Violacein [3-(1,2-dihydro- 5-(5-hydroxy-1H-indol-3-yl)-

2-oxo-3H-pyrrol-3-ilydene)-1,3-dihydro-2H-indol2-one], a purple-coloured bacterial compound,
derived from proviolacein, has a molecular weight
of 343.3 and the molecular formula C20H13N3O3
[4,5] (Fig. 1). Violacein is insoluble in water and
decomposes at >290  C (3). Its chemical structure
was speculated as a result of a series of degradation experiments which was later ascertained by
chemical synthesis [4,5]. The alkaloid is formed as a
result of oxidative coupling of 1,3-dihydro-2Hindol-2-one and 1,3-dihydro-2H-pyrrol-2-one, both
in the third position which is then replaced by a 5hydroxy-1H-indol-3-yl group at the ﬁfth position
[7]. It is formed of 3 structural units including the 5hydroxyindole, 2-pyrrolidone, and an oxindole,
with the involvement of 2 indole rings hence violacein is known as a bisindole, which falls in the
visible spectrum [6,8].
This secondary metabolite is linked to bioﬁlm
formation in the majority of violacein-producing
bacterial strains and acts as a major defence mechanism for the strain producing it [9]. The purple
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Fig. 1. The structure of violacein (Pubchem CID 11053).

pigment has been proven for its numerous biological
applications such as antimicrobial, antileishmanial,
antiviral, as well as antitumoral [10e13]. One of the
non-therapeutic applications of the pigment includes
dyeing natural and synthetic fabrics along with antimicrobial polyamide fabrics [14]. The tumoricidal
effects of violacein have been investigated in recent
years. The pigment’s efﬁcacy evaluated on in vitro
cancer models viz., colon cancer (HT29 and HCT116),
head and neck cancer (HN5), and breast cancer
(MCF-7) cell lines indicated enhanced anti-cancer
activity under hypoxic conditions [12]. Tumor invasion and metastatic matrix metalloproteinase were
inhibited by violacein treatment in MCF-7 cells [15].
The anti-tumoral effects were reported in Ehrlich
Ascites Carcinoma (EAC) and MOLT-4 leukaemia
cell lines where effective regression was achieved
both in vivo and in vitro [16,17]. Although the pigment
has been researched for its multi-sided biological
properties, studies on anticancer mechanisms are
still emerging. Tentatively, violacein has been reported to inhibit cancer progression via the PI3K/
AKT/mTOR pathway acting on cell proliferation, cell
cycle progression, and apoptosis [13].
The main tool for structural molecular biology
and computer-aided drug design is molecular
docking. The goal is to ﬁgure out what the ligand's
main binding modes are to a three-dimensional
protein structure. As a result, the intermolecular
complex produced between the two molecules is
discovered [18]. Molecular docking employs a
scoring system that can predict binding strength,
complex energy, and binding afﬁnity between the
protein and the ligand, all of which can lead to
downstream activation or inhibition [19,20]. Few
studies have tried to elucidate the antineoplastic
potential of violacein via computational studies
and have concluded that it may have activity

against cancers like pancreatic cancer, thyroid
cancer, colorectal cancer, and endometrial cancer
indicating its potential application as a broad range
of anti-cancerous drug [21]. Notwithstanding, there
is a need to identify the mechanistic basis of the
observed activity(ies) and validate the same in vitro
and in vivo.
The Epidermal Growth Factor Receptors (EGFR)
are a wide family of receptor tyrosine kinases (TKs)
seen in oesophageal, lung, breast, and head and neck
cancers. EGFR is a key player in a complicated signalling cascade that controls cancer cell proliferation,
survival, adhesion, migration, differentiation, and
signalling. EGFR has emerged as a promising option
for anti-cancer therapy due to its pivotal role in
cancer incidence and progression [22]. The abnormal
activity of EGFR, in particular, has been demonstrated to have a noteworthy role in the genesis and
development of tumour cells, where it is implicated
in a variety of cellular responses such as proliferation
and cell death [23]. Tyrosine kinase inhibitors are
small molecules that are ATP analogues that block
EGFR signalling by competing with and binding to
ATP binding sites on the intracellular catalytic kinase
domain of receptor tyrosine kinases, blocking autophosphorylation and activation of numerous downstream signalling cascades [24].
Cancers develop resistance to such EGFR inhibitors as a result of the existence or occurrence of
point mutations in the receptor's tyrosine kinase
domain. New anti-EGFR medicines with potent
therapeutic properties are desperately needed. The
overexpression and activation of EFGR in malignancies are linked to a poor patient prognosis. As a
result, EGFR is an essential molecular target for
clinical onco-therapeutics. In recent years, several
EGFR inhibitors have been discovered and clinically approved. Natural products are a great source
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for the identiﬁcation and development of innovative cancer therapy alternatives as the majority of
anticancer medicines are of natural origin [25,26].
Using omics-directed screening, the current study
aims to determine the EGFR inhibitory efﬁcacy of
violacein for its antineoplastic application and
possible mechanistic intricacies associated with the
same.

2. Materials and methods
2.1. Library and macromolecule preparation
The Protein Data Bank (PDB) is a database of
protein structures in biology. The structure of EGFR
was retrieved in PDB format from the PDB (3W2S).
With the help of version 2.4 of the PYMOL tool
(Schrodinger), water molecules were removed from
the 3-dimensional structure and examined for any
prior attachment to ligands before being saved
in.pdb format for further validation. The protein
was reﬁned and optimised using the online Galaxyweb tool (http://galaxy.seoklab.org/), after which
the active sites of the proteins were determined
using the online CASTp server.
2.2. Ligand optimization
The chemical structures of the phytochemical were
obtained in.sdf format from PubChem. Violacein
structure (PubChem CID 11053), carboplatin (PubChem CID 426756), and Geﬁtinib (PubChem CID
123631) structures were thus downloaded. Using the
OpenBabel programme, the obtained .sdf ﬁles were
transformed into PDB ﬁles by adding hydrogen
atoms. Finally, the PDB data were geometrically
enhanced using the ArgusLab software version 4.0.1.
2.3. Protein validation
The protein structure validation and evaluation of
its amino acid residues in the allowed and favoured
regions were performed using PROCHECK to
obtain the Ramachandran plots. The proteins were
deemed ﬁt for molecular docking as they had a
higher number of residues in the favoured region.
2.4. Molecular docking and interaction
To evaluate the inhibition potential of these ligands, molecular docking was carried out against
prepared proteins using the AutoDock Vina in PyRx
(https://pyrx.sourceforge.io/). The prepared protein
and ligand ﬁles were uploaded in their .pbd format
and converted to. pdbqt format and validated for the
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conﬁrmation of hydrogen molecule addition. Once
conﬁrmed, the required changes were incorporated,
followed by the recognition of active sites, assignment, and generation of a grid box to cover the
binding sites. Once docking was performed, results
were available in multiple poses and models with
various binding afﬁnities and RMSD values, out of
which, the models with the highest binding afﬁnities
were selected and saved (.pdb format) for visualization of the interaction between the ligands and the
proteins.
The best-docked poses from the results attained
from the docking procedure were further visualized
using the discover studio software which provides
the near-able binding residues, which conﬁrmed the
best docking poses of the selected ligands and their
binding afﬁnities were noted.
2.5. ADMET evaluation
The structures of Violacein compound were
downloaded from Pubchem tool (https://pubchem.
ncbi.nlm.nih.gov/) and were converted to their canonical simpliﬁed molecular-input line-entry system
(SMILES). They were submitted to the SwissADME
(http://www.swissadme.ch/) and PreADMET tool to
determine the metabolism, excretion, distribution,
toxicity, and absorption characteristics of a compound. The organ toxicities and toxicological endpoints of the isolated compounds were predicted
using PreADMET (http://biosig.unimelb.edu.au/
pkcsm/prediction).

3. Results
One of the factors linked to cancer development is
abnormal protein tyrosine kinase activity. EGFR
tyrosine kinases are involved in cell proliferation,
differentiation, angiogenesis, apoptosis inhibition,
and cell cycle progression, among other functions
[27]. As a result, it's predictable that aberrant tyrosine kinase activity can contribute to the emergence
and maintenance of many malignancies, predominantly breast adenocarcinoma. Inhibition of EGFRTK has been shown to be successful in cancer
treatment [28]. However, although there are multiple efﬁcient anticancer medications and active inhibitors against a variety of protein targets, rising
resistance and a slew of adverse effects need the
development of new, better treatments [29,30].
3.1. Active site prediction
The active site amino acids on 3W2S were identiﬁed using online Castp tool as shown in Fig. 2.
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Fig. 2. The sequence depicts residues forming the binding pocket along with the binding pocket of 3W2S.

3.2. Protein structure validation

3.3. Molecular docking interaction

The protein was evaluated using Rampage. After
initial validation and reﬁnement of the protein,
revealed more than 90% of residues in the allowed
region, indicating that the protein is stable enough
to proceed with further molecular docking experiments. Fig. 3 depicts the percentage of residues
in the favoured (93.8%) and allowed (5.5%) regions.

The molecular interaction studies performed
through molecular docking of violacein against
EGFR proteins exhibited strong binding afﬁnities
and molecular interactions.
Highest binding afﬁnity ( 10.9 kcal/mol) was
observed with EGFR tyrosine kinase, (3W2S), which
displayed 3 hydrogen bonds with amino acid residues

Fig. 3. Ramachandran plot analysis of selected 3D protein model by PROCHECK serve.
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LEU788, MET793, and ASP855 as shown in Fig. 4
supporting pi-sigma and pi-alkyl bonds in the interaction when visualized.
In comparison to violacein interaction over the
standard EGFR inhibitors, binding of standard drug
Geﬁtinib, which is a known inhibitor of EGFR via
action on the PI3K/Akt/mTOR pathway revealed
binding afﬁnity of 8.4 kcal/mol for Geﬁtinib (Fig. 5).
3.4. ADMET proﬁling
The Kp value in cm/s indicated the skin absorption and the Kp value ( 6.45) depicted lower skin
permeability of violacein compound. Furthermore,
the studies predicted that the compound doesn’t
show Bloodebrain barrier (BBB) permeation but
they did show high gastrointestinal (GI) absorption.

Out of the cytochromes, violacein inhibited only
CYP1A2.
The ﬁndings of Pre-ADMET analysis are shown in
Table 1 and the ADMET prediction in Fig. 6. The

Table 1. Pre-ADMET analysis of violacein compound.
Model Name

Predicted Value

hERG I inhibitor
hERG II inhibitor
Oral Rat Acute Toxicity (LD50)
Oral Rat Chronic Toxicity (LOAEL)
T.Pyriformis toxicity
Minnow toxicity
AMES toxicity
Max. tolerated dose (human)
Hepatotoxicity
Skin Sensitisation

No
Yes
2.413
1.258
0.285
2.084
No
0.728
Yes
No

Fig. 4. Interaction of violacein with 3W2S.

Fig. 5. Interaction of Geﬁtinib with 3W2S.

mol/kg
log mg/kg_bw/day
ug/L
mM
log mg/kg/day
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Fig. 6. ADMET prediction of violacein compound.

pink region determines the optimal range for each
property (Size: MW between 343.34 g/mol; lipophilicity: XLOGP3 2.74; polarity: TPSA between
101.47 Å2; solubility: log S not higher than 6). AMES
toxicity, Skin Sensitisation, and hERG potassium
channel inhibitor were the few parameters used to
predict the toxicity of violacein. The results conﬁrm
that the violacein molecule is devoid of risk of
toxicity.

4. Discussion
Docking studies are considered a helpful method
in connecting structurally diverse items in an ordered manner. Molecular docking employs a
scoring system that can predict binding strength,
complex energy, and binding afﬁnity between the
protein and the ligand, all of which can lead to
enzyme activation or inhibition. It is the most
frequent method used in drug design because of its
capacity to predict, the degree of precision, and
conformation of small molecule ligands with the
target binding site [19,20,31].
Several computational studies performing molecular docking of natural compounds against EGFR
concluded natural compounds to have higher binding afﬁnities against EGFR as compared to FDAapproved standard therapeutic drugs [32,33]. Violacein, a pigment obtained from Chromobacterium violaceum is gaining popularity due to its signiﬁcant
biological activity and pharmacological promise, and
a comparison of the molecular docking interaction
between violacein and the standard prescribed EGFR

inhibitor, Geﬁtinib, revealed a higher binding afﬁnity
of violacein against the kinase with a higher number
of conventional hydrogen bonds formed between the
latter and the receptor protein [21]. This is in agreement with other computational studies of violacein
that identiﬁed the compound as a potential cancer
therapeutic agent [21].
Geﬁtinib is a ﬁrst-generation EGFR inhibitor
approved for clinical use by the Food and Drug
Administration, made from anilinoquinazoline that
was discovered in 1996 [34,35]. It is an orally
bioavailable, EGFR inhibitor of slow molecular
weight that inhibits only tyrosine kinase activity and
not serineethreonine kinase activity [36]. It is
thought to upregulate the CDK inhibitor p27 and
downregulate the transcription factor c-fos, resulting in CDK activity inhibition and cell-cycle arrest in
the G1 phase [37]. Results of this study indicate that
violacein shows an effective binding towards EGFR.
It could also be speculated that violacein demonstrated inhibitory action on EGFR via similar pathways, although more studies are required to
validate this theory.
Any potential drug could become ruined due to its
limited metabolism, excretion, distribution, toxicity,
and absorption characteristics. Understanding
pharmacokinetics, or the fate of a molecule inside
the body, is critical throughout the development of
innovative medicine. Theoretically, individual variables known as ADMET variables are often used to
determine these factors, and computer models are
typically employed in the place of experimental
methods. Various Log P and S prediction tools, such
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as ILOGP, XLOGP3, WLOGP, ESOL, and SILICOSIT, were used to compile the results on lipophilicity
and hydrophilicity of the speciﬁed ligand molecule
in this study. The logarithm of the ratio of the concentration of drug ingredient between two solvents
in an un-ionised form is used to determine the lipophilicity of a molecule.
For druggable chemicals, the Lipinski rule prescribes a maximum of 5. At the pre-clinical stage of
drug development, Lipinski's rule of ﬁve states that
any chemical that violates more than two criteria is
impermeable or poorly absorbed [38]. The lower the
log P values, the greater the lipophilicity of the
chemical substance. It is important to evaluate the
skin’s permeability i.e., to determine the potential
form for transdermal drug delivery. Using SwissADME, the druggable characteristics and druglikeness of the selected antiproliferative agent, violacein, were predicted using a pharmacokinetic
proﬁle and was determined to be orally bioavailable, indicating that the dye could be a potential
anticancer agent acting via the inhibition of EGFR
kinase.

5. Conclusion
The present study demonstrates the in silico molecular docking of violacein against EGFR kinase.
Violacein seems to be a promising anticancer therapeutic candidate with higher binding afﬁnities towards EGFR kinase as compared to the Geﬁtinib
positive control. Further in vitro and in vivo investigations into its antineoplastic properties in
various types of cancers as well as the molecular
pathways involved, could lead to the development
of an affordable, novel EGFR-inhibiting, an orallybioavailable anticancer agent.
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